Liposome Encapsulated Doxorubicin Citrate (Ledc) as an Alternative Therapeutic Option for Patients with Recurrent Ovarian Cancer Suffering from Doxorubicin-Related Cutaneous Toxicity
response in 20%, stable disease in 37% and progression in 9% of patients. No cutaneous toxicity was reported. Conclusion: LEDC is a well tolerated drug and a valid therapeutic option ... patients with ovarian cancer…

